Karyopharm commences two KPT-330 phase 1 studies in cancers

Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330.

Read the original post:
Karyopharm commences two KPT-330 phase 1 studies in cancers

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share